Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LYMErix Two-Dose Efficacy Data Provides 1999 Tick Season Benchmark

Executive Summary

Two-dose efficacy data included in labeling for SmithKline Beecham's LYMErix will provide an efficacy benchmark for use of the vaccine in anticipation of the 1999 Lyme disease season.

You may also be interested in...



Lymerix Two-Month Dose Expected By Mid-2000, Pediatric Data By Year-End

SmithKline Beecham's Lymerix two-month accelerated dosing regimen could receive FDA approval in the first half of 2000, Jean-Pierre Garnier, PhD, said Sept. 16 at the Bear Stearns health care conference in New York City.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS033386

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel